Latest News

• share
• favorite_border

• share
• favorite_border

• share
• favorite_border

In a clinical trial to be launched at City of Hope in November, researchers Don J. Diamond, Ph.D., Vincent Chung, M.D., and their collaborators will combine an immune-boosting vaccine and a drug that blocks a tumor’s inhibitory signal to more effectively activate a patient’s own immune system to fight his or her cancer.

• share
• favorite_border

Steven T. Rosen, M.D., provost and chief scientific officer for City of Hope, will receive a Lifetime Achievement Award from the Israel Cancer Research Fund (ICRF) on Nov. 18 at a Chicago gala attended by hundreds of supporters of cancer research. The award recognizes Rosen’s longstanding commitment to advancing science and medicine and providing extraordinary patient care.

• share
• favorite_border

With open enrollment for the Covered California health exchange now underway, City of Hope has announced an agreement with Blue Shield of California to participate in the insurer’s Individual and Family Plan products.

• share
• favorite_border

The National Institutes of Health has awarded City of Hope a five-year, $4.8 million grant to study the possible role of chemicals in the environment in the development of breast cancer during the menopausal transition in women.

• share
• favorite_border

Renowned health care leader Glenn D. Steele Jr., M.D., Ph.D., the recent past president and chief executive officer of Geisinger Health System, will join the City of Hope board of directors beginning Jan. 1, 2016.

• share
• favorite_border

The National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) has awarded a $2.2 million grant to help City of Hope researchers explore the underlying mechanisms of graft-versus-host disease, the leading cause of long-term sickness and death following transplantation of bone marrow cells from a donor.

• share
• favorite_border

Called “The Miracle of Science with Soul,” the new campaign is the first-ever broad communications program by City of Hope, which pioneered the technology behind cancer treatment game-changers trastuzumab (Herceptin®), bevacizumab (Avastin®) and rituximab (Rituxan®), as well as synthetic human insulin for the treatment of diabetes. The campaign is centered around the real stories of six patients who showcase how City of Hope fuses science and research innovation with compassionate care in order to save lives.

• share
• favorite_border

Renowned health care leader Glenn D. Steele Jr., M.D., Ph.D., the recent past president and chief executive officer of Geisinger Health System, will join the City of Hope board of directors beginning Jan. 1, 2016.

• share
• favorite_border

Nationally renowned breast cancer and ovarian cancer specialist Victoria L. Seewaldt, M.D., has joined City of Hope as the Ruth Ziegler Chair in Population Sciences. An expert in cancer prediction and prevention, Seewaldt will advance the institution’s efforts to ensure its research reflects and represents the diversity within City of Hope’s community.

• share
• favorite_border

The Judy and Bernard Briskin Family Foundation has announced a gift to launch the new Judy and Bernard Briskin Center for Multiple Myeloma Research at City of Hope, the third named center within City of Hope’s new Hematologic Malignancies and Stem Cell Transplantation Institute. The generous gift will enable the institution to further its already considerable accomplishments in the field of myeloma treatment and research.

• share
• favorite_border

Renowned research scientist Debbie C. Thurmond, Ph.D., has joined City of Hope as professor and founding chair of the Department of Molecular and Cellular Endocrinology within the institution’s new Diabetes & Metabolism Research Institute. Thurmond will lead City of Hope’s efforts to develop new diabetes treatments, focusing on potential therapies that can reverse or prevent the onset of the disease.

• share
• favorite_border

• share
• favorite_border

A multinational team of physicians and scientists from City of Hope, the San Francisco Bay area and Europe recently reported success of a phase II clinical trial of a novel drug against essential thrombocythemia (ET), one of three myeloproliferative neoplasms (MPNs).

• share
• favorite_border

Physicians in the newly launched Diabetes & Metabolism Research Institute at City of Hope are now providing islet cell transplantation to suitable candidates through a clinical trial that they believe will be the first step in a multipronged effort to permanently cure type 1 diabetes.

• share
• favorite_border

Already pioneers in the use of immunotherapy, City of Hope researchers are now testing the bold approach to cancer treatment against one of medicine’s biggest challenges: brain cancer. This month, they will launch a clinical trial using patients’ own modified T cells to fight advanced brain tumors.

• share
• favorite_border

• share
• favorite_border

• share
• favorite_border